Get the Stockscreener App
12.30
0.74%
0.09
Arcturus Therapeutics Holdings Inc stock is traded at $12.30, with a volume of 361.58K.
It is up +0.74% in the last 24 hours and down -5.31% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
See More
Previous Close:
$12.21
Open:
$11.98
24h Volume:
361.58K
Relative Volume:
0.81
Market Cap:
$333.58M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-10.60
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-17.67%
1M Performance:
-5.31%
6M Performance:
-27.52%
1Y Performance:
-43.00%
1-Day Range:
$11.87
$12.41
1-Week Range:
$11.87
$15.18
52-Week Range:
$8.04
$25.88
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
12.30 | 331.14M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Is Arcturus Therapeutics Holdings Inc. stock overvalued or undervaluedSwing Trade Entry Points For Fast Growth - jammulinksnews.com
How does Arcturus Therapeutics Holdings Inc. compare to its industry peersBreakout Stocks Recommendation With Proven Results - jammulinksnews.com
High Growth US Tech Stocks To Watch In August 2025 - simplywall.st
Is Arcturus Therapeutics Holdings Inc. a growth stock or a value stockRetirement Planning Review With Proven Results - jammulinksnews.com
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load? - simplywall.st
Why is Arcturus Therapeutics Holdings Inc. stock attracting strong analyst attentionBeginner Investor Report With Low Risk - jammulinksnews.com
Published on: 2025-07-29 23:05:26 - metal.it
Sector ETF Data Correlates with Strength in Arcturus Therapeutics Holdings Inc.Investment Playbook for Growing Markets Shared - metal.it
Arcturus Therapeutics Holdings Inc. Sees Relief Buying After Extended DropQuick Gain Stock Watch With Indicators Reviewed - metal.it
Using R and stats models for Arcturus Therapeutics Holdings Inc. forecastingFree Real-Time Analysis With Entry Targets - Newser
Price Floor Holding on Arcturus Therapeutics Holdings Inc. — Rebound PossibleSmart Investment Tips Gaining Popularity Among Analysts - metal.it
How Arcturus Therapeutics Holdings Inc. stock performs during market volatilityCapital Growth Summary Over Five Years - Newser
Arcturus Therapeutics Holdings Inc. Shows Risk Reward Favoring UpsideGrowth Focused Entry Plan Suggestions Issued - metal.it
What are analysts’ price targets for Arcturus Therapeutics Holdings Inc. in the next 12 monthsEarnings Report Insights With Low Risk - jammulinksnews.com
Does Arcturus Therapeutics Holdings Inc. stock perform well during market downturnsFree Stock Market Real-Time Monitoring - jammulinksnews.com
Why Arcturus Therapeutics Holdings Inc. stock attracts strong analyst attentionTrading Volume Anomaly Summary and Insight - Newser
New York State Common Retirement Fund Sells 1,100 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
What are Arcturus Therapeutics Holdings Inc. company’s key revenue driversBreakthrough financial growth - jammulinksnews.com
What makes Arcturus Therapeutics Holdings Inc. stock price move sharplyBuild wealth steadily with proven strategies - jammulinksnews.com
What catalysts could drive Arcturus Therapeutics Holdings Inc. stock higher in 2025Unlock powerful trading strategies for gains - jammulinksnews.com
Arcturus Therapeutics Holdings Inc. Stock Support and Resistance Levels You Should KnowFree Stock Market Swing Trading Strategies - metal.it
Is Arcturus Therapeutics Holdings Inc. Stock Overbought or Oversold RSI Indicator AnalysisMinimized Risk Maximum Return - Newser
What institutional investors are buying Arcturus Therapeutics Holdings Inc. stockInvest confidently with data-driven strategies - jammulinksnews.com
Is Arcturus Therapeutics Holdings Inc. a good long term investmentFree Investment Community - PrintWeekIndia
Does Arcturus Therapeutics Holdings Inc. stock pay reliable dividendsOutstanding capital returns - jammulinksnews.com
What analysts say about Arcturus Therapeutics Holdings Inc. stockExceptional trading performance - PrintWeekIndia
What drives Arcturus Therapeutics Holdings Inc. stock priceConsistent high-yield stocks - PrintWeekIndia
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 - BioSpace
Arcturus Therapeutics Holdings Inc. Stock Analysis and ForecastTriple-digit wealth increases - Autocar Professional
Arcturus Therapeutics to Attend Upcoming Investor ConferencesJuly 23, 2025 - BioSpace
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):